Future of Drug Discovery – Détails, épisodes et analyse

This episode is a discussion between ⁠Rahmad Akbar, Senior Data Scientist in Antibody Design at Novo Nordisk and Murat Tunaboylu⁠, Co-Founder and CEO of Antiverse⁠.

You will learn:

• The impact antibody design has on the world.
• How AI is helping to push antibody design forward, bringing new therapies to patients.
• What will antibody design look like in the future?

Rahmad's LinkedIn page.

Rahmad's Personal Website.

Antibody Origami: Here.

Rahmad's Previous and Existing Team: Victor Greiff (GreiffLab). Paolo Marcatili, Ludovica Beltrame, Rasmus Høiberg-Nielsen (Antibody Design at Novo Nordisk).

"And a big shout out to budding antibody designers (scientists) everywhere especially from my home country Indonesia!' - Rahmad.

Be sure to like, rate and review the podcast if you enjoyed this episode! Visit our website: https://www.antiverse.io/ Follow us: LinkedIn: ⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠⁠⁠⁠⁠ X: ⁠⁠⁠⁠⁠⁠⁠https://twitter.com/AntiverseHQ⁠⁠

This episode is a discussion between Paul Essery, Host of 'The Tech Business Podcast' and Murat Tunaboylu Co-Founder and CEO of Antiverse.

You will learn:

• The CEO journey and how Antiverse was founded.
• How artificial intelligence is solving challenging targets in antibody discovery.
• Successes and challenges of being a biotech founder (+advice for aspiring entrepreneurs).

Be sure to like, rate and/or review the podcast if you enjoyed it!

Visit our website: https://www.antiverse.io/

Follow us:

LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠⁠⁠⁠

X: ⁠⁠⁠⁠⁠⁠https://twitter.com/AntiverseHQ⁠⁠

In this episode, we speak with Alan Nafiiev, Co-Founder and CEO of ‘RECEPTOR.AI’, an Artificial Intelligence (AI)-drug discovery company focused on screening small drug molecule candidates against difficult-to-drug targets.

Alan gives some key insights into the history of Receptor AI, the company's successes and obstacles, and how Receptor AIs 'software as a service' (SaaS) and services are streamlining the drug discovery process for pharmaceutical and biotech companies. He also discusses how Receptor AIs technology can automate and customise drug discovery pipelines.

To conclude, Alan explains Receptor AIs plans for 2023 - branching into membranotropic drug discovery for cancer and cardiovascular diseases, through designing drugs against unique membrane environments.  

Things mentioned:

• Sergii Starosyla, Co-Founder and CTO of Receptor AI.
• Semen Yesylevskyy, Co-Founder and CSO of Receptor AI. 
• Enamine, a partner to Receptor AI. 

Additional Materials: 

• SIRT1 Case Study
• BRD4 Case Study
• Selectivity Benchmark
• Platform Benchmarks and Tests
• Bifunctional Protein Degradars
• Product Deck
• End-to-End Drug Candidate Design via Active Learning

Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.

Arctoris COO Tom Fleming talks about automation and building a small molecule discovery platform

In this episode, our guest Assistant Prof. Tim Jenkins talks about snakebites and how to use AI to design broadly neutralising antibodies against venoms. Tim takes us through his experience at Milner Therapeutics Institute and shares his passion and vision for connecting academia and startups/industry players. In the second half of this talk, Tim explains the complexity in the venom domain and the challenges that lie ahead for the commercialisation of antivenom antibodies. 

PS: Recently, with InstaDeep, Tim has posed a snake antivenom challenge as part of the largest hackathon in Africa.

In episode 4, Murat talks with Andrew C. R. Martin, Professor of Bioinformatics and Computational Biology at UCL, about abYsis (a fully integrated antibody discovery system) and the latest antibody developability tools!

Following the origin story of abYsis, you will hear the differences between the public and commercial versions such as data persistence and security, as well as new tools such as abYmod and abYdraw.  

At the end of the talk, the discussion moves into developability (stability and Immunogenicity).

Antiverse - Engineering the future of drug discovery - https://www.antiverse.io/

To obtain an abYsis license contact Chemogenomix. 

To be an abYdraw beta tester contact Andrew Martin. 

Future of Drug Discovery Episode #3

In this session, Murat talks with Konrad Krawczyk, Assistant Professor SDU and Founder of NaturalAntibody. 

We will be covering Mr Natural Antibody's views on developing and using bioinformatics tools to analyse and discover biologics.

Other topics in this episode:

- Changing role of bioinformatics from assisting to being the main driver in biologics discovery
- 99% of the job is to get quality data, 1% is computational methods
- Collecting data from Patents, Scientific Publications, NGS, Therapeutics from FDA
- Developing models for binding prediction and biophysical properties
- Predictions of binding and developability, database, tool access, and expertise
- Interpretability of ML models

Antiverse - Engineering the future of drug discovery - https://www.antiverse.io/

In this episode, Murat talks with Ryan Kelly about Abveris (employee #3) and how to run 100+ discovery campaigns against challenging targets.

FODD 1 - Victor Greiff - Immunology and Machine Learning Applied to Drug Discovery

In this episode, we speak with ⁠⁠Björn Schimmöller, Co-Founder and CEO of iuvantium, a synthetic immunobiology company developing new modalities for the next generation of immunotherapies.

Host: ⁠⁠Murat Tunaboylu⁠⁠, Co-Founder and CEO of Antiverse.

You will learn:

• The founding journey of iuvantium from Oxford University.
• How Iuvantium is enhancing immune system efficiency and reducing clinical trial uncertainty using inorganic chemistry.
• ‘Decoding’ the immune system and how personalised medicine may lead to the next leaps in immunotherapy.

Things mentioned:

• ⁠⁠AstraZeneca COVID-19 vaccine
• John Austyn - CSO and Co-Founder of Iuvantium
• Ralph Steinman
• Farooq Khan - AI Architect at Iuvantium
• ‘Artificial Lymph Nodes’
• Simon Sinek - The Infinite Game

Additional Materials:

• ⁠Contact iuvantium: info@iuvantium.com⁠⁠
• iuvantium website: https://iuvantium.com/
• iuvantium LinkedIn: https://www.linkedin.com/company/iuvantium/

First time hearing about Antiverse?

Antiverse is an artificial intelligence-driven techbio company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Headquartered in Cardiff, UK and with offices in Boston, MA, Antiverse combines state-of-the-art machine learning techniques and advanced cell line engineering to develop de novo antibody therapeutics. With a primary focus on establishing long-term partnerships, Antiverse has collaborated with two top 20 global pharmaceutical companies. In addition, they are developing a strong internal pipeline of antibodies against several challenging drug targets across various indications.

For more information, please visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.antiverse.io⁠⁠

Never miss a future event!

We'll notify you when a new event is scheduled. Fill out ⁠⁠⁠⁠⁠⁠this form⁠⁠⁠⁠⁠⁠ to sign up for marketing communications from Antiverse. We post about upcoming events on LinkedIn and Twitter.

LinkedIn: ⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/antiverse/⁠⁠⁠⁠⁠⁠

X: ⁠⁠⁠⁠⁠⁠https://twitter.com/AntiverseHQ⁠⁠